Administration Of A New Tetravalent Canine Leptospirosis Vaccine Has No Adverse Effect On Either The Safety Or Efficacy Of An Intranasal Kennel Cough Vaccine — ASN Events
  1. Schedule
  2. Session 4 Poster Session
  3. Administration Of A New Tetravalent Canine Leptospirosis Vaccine Has No Adverse Effect On Either The Safety Or Efficacy Of An Intranasal Kennel Cough Vaccine

Administration Of A New Tetravalent Canine Leptospirosis Vaccine Has No Adverse Effect On Either The Safety Or Efficacy Of An Intranasal Kennel Cough Vaccine (#73)

Norman Spibey 1 , Eric Klaasen 2 , David Sutton 1 , Leo van der Waart 2 , Martyn Woods 1
  1. MSD Animal Health, Milton Keynes, Bucks, United Kingdom
  2. MSD Animal Health, Boxmeer, The Netherlands

INTRODUCTION
Recently a new European tetravalent canine leptospirosis vaccine has been developed (Nobivac® L4). This new vaccine will commonly be given to dogs mixed with the routine injectable lyophilized viral components. Studies to support this simultaneous use have been undertaken. It is common for intranasal ‘kennel cough’ vaccines to also be given to ‘at risk’ dogs during the same consultation. This study was designed to investigate any adverse effect of Nobivac L4 on the safety or efficacy of a live, bivalent (Bordetella bronchiseptica and canine parainfluenza virus), intranasal vaccine (Nobivac KC).

MATERIALS AND METHODS
Thirty-one SPF beagle puppies, 6 weeks of age, were divided into three groups. Group 1 pups were vaccinated intranasally with Nobivac KC and subcutaneously with Nobivac DHP reconstituted in Nobivac L4. Group 2 pups received just Nobivac KC and group 3 pups received Nobivac DHP reconstituted in Nobivac L4. Three weeks following vaccination all pups were challenged with pathogenic strains of Bb and CPiV. Adverse clinical signs, serum antibody titres and shedding of Bb and CPiV were recorded throughout the study.

CONCLUSION
There is no adverse effect of Nobivac L4 on either the efficacy or safety of Nobivac KC when used concurrently.